ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health Care"

  • Abstract Number: 0777 • ACR Convergence 2022

    Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study

    Arjun Raghavan1, Liam O'Neil1, Carrie Ye2 and Jeffrey Graham1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Alberta, Edmonton, AB, Canada

    Background/Purpose: The advent of immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of cancer. Patients with pre-existing autoimmune diseases (AID) were largely excluded from…
  • Abstract Number: 0791 • ACR Convergence 2022

    Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy

    Ingrid Jyssum1, Anne Therese Tveter1, Joe Sexton1, Ingrid Egeland Christensen1, Siri Mjaaland2, David Warren3, Tore K. kvien1, Kristin Hammersbøen Bjørlykke4, Grete Birkeland Kro3, Jørgen Jahnsen4, Ludvig A. Munthe3, Espen Haavardsholm1, Gunnveig Grødeland3, Sella Aarrestad Provan1, Kristin Kaasen Jørgensen4, Guro Goll1 and Silje Watterdal Syversen1, 1Diakonhjemmet Hospital, OSLO, Norway, 2Norwegian Institute of Public Health, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway, 4Akershus University Hospital, Oslo, Norway

    Background/Purpose: Humoral vaccine responses to SARS-Cov-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMIDs). Concerns have been raised regarding their…
  • Abstract Number: 0995 • ACR Convergence 2022

    Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus

    Patricia Katz1, Sofia Pedro2, Jiyoon Choi3 and Kaleb Michaud4, 1UCSF, San Rafael, CA, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3Bristol Myers Squibb, Lawrenceville, NJ, 4University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Glucocorticoids (GCs) have long been a mainstay of treatment for systemic lupus erythematosus (SLE). While GCs do provide benefit, there are potential side effects…
  • Abstract Number: 0064 • ACR Convergence 2022

    Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study

    Baptiste Chevet1, Gabriel Figueroa Parra1, Jeffrey X. Yang1, Mehmet Hocaoglu1, Shirley-Ann Osei-Onomah1, Cassondra Hulshizer1, Tina Gunderson1, Divi CORNEC2, Cynthia Crowson3 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2CHRU Brest, Brest, France, 3Mayo Clinic, Eyota, MN

    Background/Purpose: Systemic lupus erythematosus (SLE) is a disease that can damage multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular…
  • Abstract Number: 1224 • ACR Convergence 2022

    ‘No Route Map’: The Complex Healthcare Journeys of People with Fibromyalgia – a Record Linkage Study in the UK

    Rosemary Hollick, Ka-Kin Lam, Marcus Beasley, Gareth Jones, Corri Black and Gary Macfarlane, University of Aberdeen, Aberdeen, Scotland, United Kingdom

    Background/Purpose: Healthcare services for persons with fibromyalgia (FM) lack co-ordination. Patients describe feeling 'invisible' within healthcare systems and often report poor experiences of care, particularly…
  • Abstract Number: 0069 • ACR Convergence 2022

    Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset

    Geoffrey Littlejohn1, Tegan Smith2, Sabina Ciciriello3, Peter Youssef4, Claire Deakin5, Nithila Anbumurali6 and Catherine OSullivan6, 1OPAL Rheumatology Ltd, Melbourne, Australia, 2OPAL Rheumatology Ltd, Geelong, Australia, 3Melbourne Health, Melbourne, Australia, 4University of Sydney, Sydney, Australia, 5OPAL Rheumatology Ltd, Mosman, Australia, 6OPAL Rheumatology Ltd, Sydney, Australia

    Background/Purpose: Routine management of inflammatory joint disease requires clinicians to consider an abundance of factors unique to each patient when deciding on the most appropriate…
  • Abstract Number: 1286 • ACR Convergence 2022

    Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center

    Joad Eseddi1, DeAnne Carmichael2, Shannon Wishin3 and Puneet Bajaj2, 1UT Southwestern School of Medicine, Dallas, TX, 2UT Southwestern Medical Center, Dallas, TX, 3UT Southwestern Medical Centre, Dallas, TX

    Background/Purpose: Biological drugs have revolutionized the treatment of rheumatic diseases. However, increasing the use of biologics over the past few years has directly contributed towards…
  • Abstract Number: 0076 • ACR Convergence 2022

    Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database

    Ko-Jen Li1, Kuo-Cherh Huang2, Chia-Cheng Lin3 and Chia-Li Chang2, 1National Taiwan University Hospital, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan, 3Chugai Pharma Taiwan Ltd., Taipei, Taiwan

    Background/Purpose: There is a growing concern over the rise of polypharmacy, arguably one of the most pressing prescribing challenges. The option of biologic monotherapy is…
  • Abstract Number: 1287 • ACR Convergence 2022

    Are the American College of Rheumatology’s Web-Based Patient Education Materials Easy for Patients to Read and Comprehend?

    Ugochukwu C Nweke1, Sobia Hassan2, Usama Ahmad3 and Meenakshi Jolly4, 1Rush University,Graduate College, Chicago, IL, 2Rush University Medical Center, Chicago,IL, Chicago, IL, 3Rush Univesity Medical Center, Chicago, IL, 4Rush University Medical Center, Chicago, IL

    Background/Purpose: Patient education materials (PEMs), obtainable from online resources, can be accessed by patients and physicians and used to supplement the medical information provided by…
  • Abstract Number: 0359 • ACR Convergence 2021

    Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)

    Marco Garrido-Cumbrera1, Denis Poddubnyy2, Christine Bundy3, Laura Christen4, Raj Mahapatra5, Souzi Makri6, Carlos Jesús Delgado-Domínguez7, Sergio Sanz-Gomez7, Pedro Plazuelo-Ramos8 and Victoria Navarro-Compán9, 1Health & Territory Research (HTR), University of Seville, Sevilla, Spain, 2Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 3Cardiff University, Cardiff, Wales, United Kingdom, 4Novartis Pharma AG, Basel, Switzerland, 5Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, 6Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, 7Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, 8Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, 9Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain

    Background/Purpose: The journey of axial spondyloarthritis (axSpA) for most patients is slow and arduous. The goal of this analysis is to assess the journey to…
  • Abstract Number: 0494 • ACR Convergence 2021

    The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States

    Sharon Dowell1, Huifeng Yun2, Jeffrey Curtis3, Lang Chen4, Manuela Pedra-Nobre5, Dianne Wollaston6, SAWSAN NAJMEY7, Cynthia Lawrence-Elliott8, Theresa Lawrence-Ford9, Heather North10, Robin Dore11, Soha Dolatabadi12, Thaila Ramanujam13, Anne Winkler14, Stacy Kennedy15, Stephanie Ott16, Stephanie Ledbetter17, Grace Wright18 and Gail Kerr19, 1Howard University College of Medicine, Washington, DC, 2University of Alabama Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama, Birmingham, AL, 5North Jersey Rheum. Center, Westfield, NJ, 6Memorial Advanced Rheumatology, Houston, TX, 7Midstate Rheumatology Center, PA, Freehold, NJ, 8North Georgia Rheum Group, Atlanta, GA, 9North Georgia Rheum Group, Atlanta, MD, 10Pardee UNC, Hendersonville, NC, 11Robin K. Dore, MD Inc, Tustin, CA, 12Soha Dolatabadi, MD, Los Angeles, CA, 13Santa Cruz Rheumatology, Inc., Santa Cruz, CA, 14Winkler Medical Practice, Springfield, MO, 15Rowan Diagnostic Clinic, Concord, NC, 16Fairfield Medical Center, Carroll, OH, 17University of Alabama at Birmingham, Birmingham, AL, 18Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, 19Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC

    Background/Purpose: The overall success of RA therapy is dependent on access to specialty care, insurance coverage and effective management of associated comorbidities. Whether RA disease…
  • Abstract Number: 0612 • ACR Convergence 2021

    Rheumatology Care for the Underserved in Central Texas

    Veena Patel, Rajvi Patel and Kevin Hackshaw, Dell Medical School - UT Health Austin, Austin, TX

    Background/Purpose: Health disparities exist among the uninsured and access to rheumatology is incredibly limited to this patient population. We reside in a state without Medicaid…
  • Abstract Number: 0615 • ACR Convergence 2021

    Socioeconomic Characteristics Associated with Electronic Health Care Utilization in an Urban Rheumatology Clinic During the COVID-19 Pandemic

    Jenna Thomason1, Bryanna Mantilla2, Alison Bays1, Irvin Huang1 and Grant hughes1, 1University of Washington, Seattle, WA, 2George Washington University, Arlington, VA

    Background/Purpose: In the US, the COVID-19 pandemic has prompted increased utilization of telemedicine (TM), electronic patient portals (EPPs), and other electronic modalities of health care…
  • Abstract Number: 0629 • ACR Convergence 2021

    Patient and Physician Satisfaction with Telemedicine Utilization for Delivery of Care in Patients with SLE – A Single Centre Experience

    Tanmayee Bichile1, Amanda Bembic2, Susan Manzi1 and Sonia Manocha1, 1Allegheny Health Network, Pittsburgh, PA, 2Allgheny Health Network, Pittsburgh, PA

    Background/Purpose: COVID 19 has forced the healthcare system to utilize telemedicine to provide dependable and timely care for patients with SLE. Telemedicine has been used…
  • Abstract Number: 0659 • ACR Convergence 2021

    Understanding the Rheumatologic Population We Serve Through Objective Analysis of Referrals and Diagnoses: Does Perception Match Actual Data?

    Kirsten Koons1, Jonida Cote2, Sanjeev Shrestha3, Melissa Band3, David Pugliese4 and Eric Newman3, 1Geisinger Medical Center, Lewisburg, PA, 2Geisinger Medical Center, Orefield, PA, 3Geisinger Medical Center, Danville, PA, 4Geisinger Medical Center, Wilkes Barre, PA

    Background/Purpose: Healthcare access in our Rheumatology Department is challenging. Fibromyalgia is perceived to occupy a large portion of clinic visits, leading to increased wait times…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology